Insmed (NASDAQ:INSM) Research Coverage Started at Rothschild & Co Redburn

Rothschild & Co Redburn assumed coverage on shares of Insmed (NASDAQ:INSM) in a research note released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $263.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Jefferies Financial Group lifted their price objective on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, August 13th. Redburn Partners set a $263.00 price target on shares of Insmed in a report on Thursday. Wells Fargo & Company increased their target price on Insmed from $171.00 to $217.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Morgan Stanley lifted their price target on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Guggenheim increased their price objective on Insmed from $125.00 to $172.00 and gave the stock a “buy” rating in a report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $187.89.

Insmed Stock Down 0.5%

Insmed stock opened at $204.00 on Thursday. The company’s 50 day simple moving average is $180.50 and its 200 day simple moving average is $134.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The firm has a market capitalization of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the prior year, the company earned ($1.27) EPS. Insmed’s quarterly revenue was up 52.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elizabeth M. Anderson sold 10,000 shares of Insmed stock in a transaction on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the transaction, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 233,650 shares of company stock valued at $41,063,785 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC bought a new stake in Insmed in the second quarter worth $173,000. Caxton Associates LLP bought a new position in Insmed in the 1st quarter valued at $441,000. Assenagon Asset Management S.A. lifted its position in shares of Insmed by 84.5% during the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Insmed during the second quarter valued at $5,578,000. Finally, Intech Investment Management LLC grew its holdings in shares of Insmed by 43.2% in the first quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock worth $7,780,000 after purchasing an additional 30,752 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.